A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Stinchcombe, T. E. [1 ]
Janne, P. A. [2 ]
Wang, X. [3 ]
Bertino, E. M. [4 ]
Weiss, J. M. [5 ]
Bazhenova, L. [6 ]
Gu, L. [3 ]
Lau, C. J. [2 ]
Paweletz, C. P. [2 ]
Jaslowski, A. J. [7 ]
Gerstner, G. J. [8 ]
Baggstrom, M. Q. [9 ]
Graziano, S. L. [10 ]
Beardenlii, J. [11 ]
Vokes, E. E. [12 ]
机构：
[1] Duke Canc Ctr, Med Oncol, Durham, NC USA
[2] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
[3] Duke Univ, Dept Biostat & Bioinformat, Durham, NC USA
[4] Ohio State Univ, James Canc Hosp, Med Oncol, Columbus, OH 43210 USA
[5] Univ North Carolina Chapel Hill, Hematol Oncol, Chapel Hill, NC USA
[6] Moores UCSD Canc Ctr, Med, La Jolla, CA USA
[7] St Marys Hosp, Med Oncol, Green Bay, WI USA
[8] Illinois CancerCare PC, Med Oncol, Peoria, IL USA
[9] Washington Univ, Sch Med, Med Oncol, St Louis, MO USA
[10] SUNY Upstate Med Univ, Med Oncol, Syracuse, NY 13210 USA
[11] Palmetto Hematol Oncol Associates, Med Oncol, Spartanburg, SC USA
[12] Univ Chicago, Med Ctr, Med Oncol, Chicago, IL 60637 USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1444P
引用
收藏
页码：522 / 522
页数：1
相关论文
共 50 条
  • [31] Randomized phase II study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer (NSCLC)
    Lynch, T. J.
    Fenton, D. W.
    Hirsh, V.
    Bodkin, D. J.
    Middleman, E.
    Chiappori, A.
    Halmos, B.
    Liu, H.
    Eton, O.
    Shepherd, W. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [32] Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients
    Xiong, Liwen
    Lou, Yuqing
    Bai, Hao
    Li, Rong
    Xia, Jinjing
    Fang, Wentao
    Zhang, Jie
    Han-Zhang, Han
    Lizaso, Analyn
    Li, Bing
    Gu, Aiqin
    Han, Baohui
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2019,
  • [33] Erlotinib in progressive pretreated advanced non-small cell lung cancer (NSCLC): Results of a phase II open-label trial
    Piantedosi, F., V
    Gilli, M.
    Caputo, F.
    Casale, B.
    Bianco, A.
    Dericoloso, A.
    Pontillo, A.
    Crispino, C.
    Giuliarini, G.
    Hengheller, M.
    Chianca, P.
    ANNALS OF ONCOLOGY, 2007, 18 : 26 - 26
  • [34] Phase I/II Trial of Dasatinib and Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
    Kim, C.
    Liu, S.
    Subramaniam, D.
    Giaccone, G.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S479 - S479
  • [35] Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis
    Sakharkar, Prashant
    Kurup, Sonali
    DISEASES, 2023, 11 (04)
  • [36] Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaive, Advanced, Non-small Cell Lung Cancer Patients Aged 70 Years or Older
    Chen, Yuh-Min
    Tsai, Chun-Ming
    Fan, Wen-Chien
    Shih, Jen-Fu
    Liu, Shih-Hao
    Wu, Chieh-Hung
    Chou, Teh-Ying
    Lee, Yu-Chin
    Perng, Reury-Perng
    Whang-Peng, Jacqueline
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (02) : 412 - 418
  • [37] Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy
    Felip, E
    Rojo, F
    Heller, A
    Foernzler, D
    Majo, J
    Klughammer, B
    Ramos, J
    Maacke, H
    Brennscheidt, U
    Baselga, J
    LUNG CANCER, 2005, 49 : S369 - S369
  • [38] A phase II trial of erlotinib monotherapy in pretreated patients (pts) with non-small cell lung cancer (NSCLC) who do not possess active EGFR mutations
    Yoshioka, H.
    Hayashi, H.
    Kiura, K.
    Takigawa, N.
    Hotta, K.
    Harita, S.
    Kamei, H.
    Bessho, A.
    Tabata, M.
    Tanimoto, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [39] ERLOTINIB AND BEXAROTENE FOR PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Dragnev, K. H.
    Seltzer, M.
    Rigas, J. R.
    DiSalvo, W. M.
    Simeone, S.
    Johnstone, D.
    Nugent, W.
    Waxman, S.
    Dmitrovsky, E.
    ANNALS OF ONCOLOGY, 2008, 19 : 102 - 102
  • [40] EXPERIENCE OF USING ERLOTINIB FOR TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Kanazawa, Kenya
    Ishida, Takashi
    Suzuki, Aya
    Tachihara, Motoko
    Minemura, Hiroyuki
    Sekine, Satoko
    Oshima, Kengo
    Yokouchi, Hiroshi
    Watanabe, Kana
    Tanino, Yoshinori
    Munakata, Mitsuru
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1310 - S1310
12345